Shots:

• The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with Gates’ funding's
• The focus of the agreement to address the disparity in access to treatments and to prioritize populations and regions bearing the greatest burden of SCD in the search for curative therapies
• The agreement builds on Novartis’ commitment to improving the lives of patients with SCD including a therapeutic pipeline and a holistic approach to diagnosis- treatment- and management of the disease

 ­ Ref: Novartis | Image: Novartis